Table 4.
Study ID | Study Group Assignment | MPXV Target Challenge Dose (PFU, IV) | Survival |
---|---|---|---|
Study 1 | Controls | 5.0E+07 | 0/3 |
ACAM2000 + Placebo | 5.0E+07 | 6/6 | |
ACAM2000 + Tecovirimat | 5.0E+07 | 7/7 | |
Study 2 | ACAM2000 + Placebo | 5.0E+07 | 3/3 |
ACAM2000 + Tecovirimat | 5.0E+07 | 2/3 | |
Study 3 | ACAM2000 + Placebo | 5.0E+07 | 3/3 |
ACAM2000 + Tecovirimat | 5.0E+07 | 3/3 |